Abstract
In patients with breast cancer, surgical intervention combined with preoperative chemotherapy improves breast conservation rates, and the long-term clinical results of patients undergoing preoperative chemotherapy is comparable to those receiving postoperative chemotherapy. The sequential administration of anthracycline (A) and taxanes (T) is now thought to be the most effective treatment regimen. We treated 296 patients with A and T sequentially and examined the clinical and pathological results. A total of 14% of the patients achieved a clinical complete response (cCR) and 9.5% achieved a pathological complete response (pCR). Tumor classification determined by imaging did not predict pCR, but CT findings helped determine appropriate resection margins. One hundred thirteen patients (38%) received lumptectomy following chemotherapy, and 24.7% (28/113) had positive tumor margins and the malignant cells tended to remain in invasive components. Prognosis was not associated with clinical stage and clinical response, but histopathological findings were closely related to prognosis. Future studies should attempt to develop an optimal chemotherapy regimen, set an appropriate resection margin, and find an effective treatment for patients with extensively calcified lesions.
Similar content being viewed by others
References
Inaji H, Komoike Y, Motomura K,et al: Breast conserving treatment after neoadjuvant chemotherapy in large breast cancer.Breast Cancer 9:20–25, 2002.
van der Hage, JA, van de Velde CJ, Julien JP,et al: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902.J Clin Oncol 19:4224–4237, 2001.
Singletary SE: Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer.Am J Surg 182:341–346, 2001.
von Minckwitz, G, Costa SD, Eiermann W,et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.J Clin Oncol 17:1999–2005, 1999.
Bear HD, Anderson S, Brown A,et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project B-27.J Clin Oncol 21:4165–4174, 2003.
Akashi-Tanaka S, Fukutomi T, Sato N,et al:The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.Ann Surg 239:238–243, 2004.
Nakamura S, Kenjo H, Nishio T,et al: Efficacy of 3D-MR mammography for breast conserving surgery after neoadjuvant chemotherapy.Breast Cancer 9:15–19, 2002.
Kaufmann M, von Minckwitz, Smith R,et al: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations.j Clin Oncol 21:2600–2608, 2003.
Rouzier R, Mathieu MC, Silderis L,et al: Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors.Cancer 101:918–925, 2004.
Chen AM, Meric-Bernstam F, Hunt KK,et al: Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center Experience.J Clin Oncol 22:2303–2312, 2004.
Motomura K, Egawa C, Komoike Y,et al: Controversy in regard with breast conservation treatment.Gann-no Rinshou 31:168–175, 2004 (in Japanese).
Matsuo K, Fukutomi T, Tsuda H,et al: Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.Breast Cancer 9:75–81, 2002.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Fukutomi, T. Clinical practice and outcome of breast-conserving treatment: The effectiveness of preoperative systemic chemotherapy. Breast Cancer 13, 147–151 (2006). https://doi.org/10.2325/jbcs.13.147
Issue Date:
DOI: https://doi.org/10.2325/jbcs.13.147